金黄色葡萄球菌复合群新成员:银白葡萄球菌与施韦策葡萄球菌的鉴定意义
ESGS立场文件基于PubMed检索综述银白葡萄球菌与施韦策葡萄球菌的微生物学特征与临床意义,指出银白葡萄球菌致病性似与经典金黄色葡萄球菌相近,施韦策葡萄球菌尚无感染报告,建议常规报告暂不在金黄色葡萄球菌复合群内区分两种新种,耐甲氧西林分离株按MRSA管理并直接通知临床。
要点
- 常规报告暂不区分复合群内新种,除非证据显示致病性或临床结局明显不同
- 研究目的下鼓励有条件的实验室区分银白葡萄球菌与施韦策葡萄球菌
- 如明确报告新种须加注「金黄色葡萄球菌复合群成员」以防混淆
核心结论
- 常规报告目的下建议暂不在金黄色葡萄球菌复合群内区分银白葡萄球菌与施韦策葡萄球菌。
- 如明确报告新种应加注「金黄色葡萄球菌复合群成员」以防与低致病或不致病葡萄球菌混淆。
- 耐甲氧西林分离株应按MRSA推荐处理,诊断实验室应直接联系并告知临床医生。
研究设计与样本
- ESGS成员立场文件,检索PubMed中银白葡萄球菌与施韦策葡萄球菌相关文献。
- 综述两菌主要特征并据此提出微生物学诊断、监测及感染防控结论。
主要发现
- 银白葡萄球菌与施韦策葡萄球菌为近期确立的凝固酶阳性新种,属金黄色葡萄球菌复合群。
- 澳大利亚与英国已有耐甲氧西林银白葡萄球菌报告。
- 越来越多证据显示银白葡萄球菌致病性与经典金黄色葡萄球菌相似。
- 迄今尚无施韦策葡萄球菌感染报告。
关键数值与推荐
- 常规报告不区分复合群内新种,直至有证据显示致病性或临床结局明显不同。
- 研究目的下有条件的实验室鼓励区分银白葡萄球菌与施韦策葡萄球菌。
- 明确报告新种时须加注「金黄色葡萄球菌复合群成员」。
- 耐甲氧西林分离株按MRSA推荐处理并直接通知临床。
临床怎么用
- 常规微生物报告不必区分复合群内新种,减少不必要的临床困惑。
- 研究或明确报告新种时加注复合群说明,避免误判为低致病葡萄球菌。
- 耐甲氧西林分离株按MRSA防控并由实验室直接联系临床医生。
局限性
- 两菌流行病学、医学意义与传播风险知识有限且部分矛盾,难以给出确定性建议。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Staphylococcus argenteus and Staphylococcus schweitzeri, previously known as divergent Staphylococcus aureus clonal lineages, have been recently established as novel, difficult-to-delimit, coagulase-positive species within the S. aureus complex. Methicillin-resistant strains of S. argenteus are known from Australia and the UK. Knowledge of their epidemiology, medical significance and transmission risk is limited and partly contradictory, hampering definitive recommendations. There is mounting evidence that the pathogenicity of S. argenteus is similar to that of 'classical' S. aureus, while as yet no S. schweitzeri infections have been reported. AIM: To provide decision support on whether and how to distinguish and report both species. SOURCES: PubMed, searched for S. argenteus and S. schweitzeri. CONTENT: This position paper reviews the main characteristics of both species and draws conclusions for microbiological diagnostics and surveillance as well as infection prevention and control measures. IMPLICATIONS: We propose not distinguishing within the S. aureus complex for routine reporting purposes until there is evidence that pathogenicity or clinical outcome differ markedly between the different species. Primarily for research purposes, suitably equipped laboratories are encouraged to differentiate between S. argenteus and S. schweitzeri. Caution is urged if these novel species are explicitly reported. In such cases, a specific comment should be added (i.e. 'member of the S.aureus complex') to prevent confusion with less- or non-pathogenic staphylococci. Prioritizing aspects of patient safety, methicillin-resistant isolates should be handled as recommended for methicillin-resistant Staphylococcus aureus (MRSA). In these cases, the clinician responsible should be directly contacted and informed by the diagnosing microbiological laboratory, as they would be for MRSA. Research is warranted to clarify the epidemiology, clinical impact and implications for infection control of such isolates.
引用
- Becker K, Schaumburg F, Kearns A, et al. Implications of identifying the recently defined members of the Staphylococcus aureus complex S. argenteus and S. schweitzeri: a position paper of members of the ESCMID Study Group for Staphylococci and Staphylococcal Diseases (ESGS). Clin Microbiol Infect. 2019. PMID: 30872103. doi:10.1016/j.cmi.2019.02.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。